Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Books
  • Manufacturing
  • Health
  • Technology
  • Financial
  • Book Release
ncarol.com

Baebies Announces FDA Acknowledgement of Emergency Use Notification for FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test – RT-PCR within 17 Minutes
ncarol.com/10109576

Trending...
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
  • Santa Your Way Announces Official 2026 Q4 Holiday Tour: Booking Open For Santa, The 5-star Grinch, And Dual Character Experiences Nationwide
  • Gabby Press Earns High Praise From Feathered Quill About the Unregulated Dangers of Second Generation Corporate AI
DURHAM, N.C.--(BUSINESS WIRE)--Baebies, a growth-stage company developing innovative products to enable early disease detection and comprehensive diagnosis, today announced that the U.S. Food & Drug Administration (FDA) acknowledged the company's Emergency Use Notification (EUN) for an RT-PCR test to detect SARS-CoV-2 on the FINDER® 1.5 Instrument. The company's FINDER SARS‑CoV-2 Test is intended for the qualitative detection of RNA from the SARS-CoV-2 virus in nasopharyngeal and nasal swab specimens with RT-PCR performed within 17 minutes.

"Our FINDER SARS-CoV-2 test combines the accuracy of RT-PCR testing with a rapid turn-around time, which is made possible by our innovative digital microfluidics technology," says Richard West, Co‑Founder and Chief Executive Officer of Baebies. "We are launching the FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test to address the continued need for access to fast and accurate testing in health care facilities with high complexity laboratories. Our team has worked tirelessly for the last year to bring this to market and we are very excited to reach this important milestone."

The FINDER 1.5 platform includes a toaster-sized instrument and disposable single-use cartridge and features:
  • Small footprint at just 8 inches wide with a commercial tablet interface
  • Easy and intuitive workflow
  • Quick installation and no specialized training needed
  • Digital microfluidic technology, which minimizes sample and reagent volumes

Development of the FINDER SARS-CoV-2 Test was supported in part by funds from the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) initiative. The underlying digital microfluidics (DMF) technology is a method to programmably manipulate tiny droplets of liquid by electrical control of surface tension on a disposable cartridge. Baebies' DMF technology is protected by several hundred patents.

More on ncarol.com
  • Data Tiles Challenges the Data Product Status Quo Following Antwerp Summit
  • Inglewood Associates and Gordon Brothers Provide Update on Sale Process for 925 Euclid Avenue in Cleveland
  • Century Fasteners Corp. Exhibiting at the 2026 International Fastener Expo
  • Las Vegas Attorney Thomas Boley Publishes Free Plain-English Guide to 100 Nevada Criminal Laws, in English and Spanish
  • Bank Statement Loans Up to $30 Million: Lendmire Announces High-Net-Worth Financing

Digital microfluidics supports multifunctional assay methods – including molecular, immunoassay, and chemistry – on the same cartridge. Currently under FDA 510(k) review, FINDER tests for glucose-6-phosphate dehydrogenase (G6PD) deficiency, a genetic defect leading to anemia and severe jaundice. FINDER can efficiently test for G6PD deficiency from low blood volume (50 µL) with a turn-around time of approximately 15 minutes after sample introduction. Additionally, Baebies has a robust development pipeline and recently won the prestigious 2020 AACC Disruptive Technology Award for FINDER in a tight competition emerging as the next innovative testing solution that will transform patient care.

"In development of our FINDER SARS-CoV-2 Test, we focused on accelerating RT-PCR and sample processing for rapid results through several innovations – all made possible by digital microfluidics," noted Vamsee Pamula, co-founder and President. "This technology powers both our diagnostic platform, FINDER, and FDA-authorized newborn screening platform, SEEKER. Baebies' core focus still remains neonatal and pediatric diagnostics, however, the current COVID-19 pandemic doesn't distinguish between children and adults – everyone is at risk."

More on ncarol.com
  • NYC Big Book Award Celebrates 10th Anniversary with Announcement of 2026 Winners
  • Regional Magazines Shine at IRMA Awards
  • Nearly Two Years After Helene, KayeDinero Films Asheville's French Broad From Above
  • Asheville Producer KayeDinero Says "Human Error" Is the Point in the AI Music Era
  • Matt Zavala of Zavala Law, PC Selected to the 2027 Super Lawyers List

About Baebies

Baebies - guided by the vision that "everyone deserves a healthy start" - develops and commercializes products and services that enable early disease detection and comprehensive diagnosis. Baebies has shipped over 10 million tests. Baebies' products include SEEKER®, an FDA-authorized and CE-marked high throughput newborn screening platform, and FINDER®, a CE-marked flexible, single sample testing platform that is currently not commercially available in the U.S. The FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test have been validated but FDA's independent review of this validation is pending. Our mission is to save lives and make lives better for all by bringing new technologies, new tests and new hope to children, parents and healthcare professionals worldwide. Baebies is headquartered in Durham, North Carolina. For more information, visit baebies.com and follow on LinkedIn, Twitter and YouTube.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Gabby Press Earns High Praise From Feathered Quill About the Unregulated Dangers of Second Generation Corporate AI
  • Canadian Tint Expo 2027: Why Every Window Tinter Should Compete in Niagara Falls on April 3rd & 4th
  • Detroit Roots, Film Scores and Python Shape KayeDinero's Asheville Sound
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • Most Indiana Plane Crashes Happen Away from the State's Major Airports
  • L2 Aviation Welcomes Jason Marshall as Vice President of Sales and Business Development
  • Mom Era, Still That Girl: Family Art Tees 25% Off
  • Fashion vs. Fascism - Because Democracy Should Always Be In Style
  • From Degrassi to Cass Tech: The Unexpected Influences Behind Asheville's KayeDinero
  • Lee Gunn IV Shares Lessons From 40 Years in the Courtroom on PodNumbra Podcast
  • KayeDinero Takes "Appalachia" Above the Blue Ridge With New Aerial Music Visual
  • Michael H. Kaplan Recognized for 17 Years on PHPA Workers' Compensation Panel and Advocacy for Professional Athletes
  • International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
  • Boston Industrial Solutions Introduces Personalized Printing Training
  • Century Fasteners de Mexico Exhibiting at the 2026 Automotive & Aerospace Nearshoring Summit
  • Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
  • FOCUS Names Mark Phillips Senior Vice President of Business Development
  • Notaron Expands Online Notarization Access Following Wisconsin Approval
  • Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
_catLbl0 _catLbl1

Popular on ncarol.com

  • Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again - 171
  • Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing - 167
  • Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not - 149
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A! - 134
  • From Temecula Wine Country to Canyon Lake: Parkway Construction Transforms Outdoor Spaces for Inland Homeowners - 131
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History - 130
  • Bspin Launches Lightning-Fast Crypto Gaming Expansion With Sportsbook, Poker, VIP Rewards, and Bitcoin Lightning Network Integration - 128
  • Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million - 124
  • Gigasoft 2026 JavaScript Chart Comparison: ProEssentials, Highcharts, SciChart, LightningChart, ECharts - 121
  • Steve Thompson Launches StickyHealth to Tackle the Retention Gap in the Growing GLP 1 Market - 116

Similar on ncarol.com

  • Data Tiles Challenges the Data Product Status Quo Following Antwerp Summit
  • Inglewood Associates and Gordon Brothers Provide Update on Sale Process for 925 Euclid Avenue in Cleveland
  • Bank Statement Loans Up to $30 Million: Lendmire Announces High-Net-Worth Financing
  • Ragin' Cajun Announces New Cheeseburger Seasoning on National Cheeseburger Day
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
  • Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • Can Government Operate Better Through Innovation?
  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute